Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 31, 2007 Brian Lawler	No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
The Motley Fool October 27, 2006 Brian Lawler	Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note.
The Motley Fool December 14, 2007 Brian Lawler	FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay.
The Motley Fool January 24, 2007 Brian Lawler	Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go.
BusinessWeek January 17, 2005 Weintraub & Barrett	Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news.
The Motley Fool August 1, 2007 Brian Lawler	Neurocrine Awaits Its Destiny Neurocrine Biosciences updates investors on its plans for the rest of the year. A new marketing application was submitted for lead drug indiplon, following a negative FDA decision last year. Good news could come as soon as December 2007.
The Motley Fool September 12, 2007 Brian Orelli	Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow.
BusinessWeek June 11, 2007 Mara Der Hovanesian	Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor, the Marlborough pharmaceutical best known for its sleep drug, Lunesta.
The Motley Fool June 15, 2007 Brian Lawler	Neurocrine Moves Ahead Neurocrine resubmits a marketing application for its lead drug. Investors, take note.
The Motley Fool September 5, 2006 Brian Lawler	Neurocrine Wakes Up Indiplon The biotech company announces new drug delays. Investors, take note.
The Motley Fool October 31, 2007 Brian Orelli	A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note.
The Motley Fool July 18, 2006 Brian Lawler	Neurocrine's Tale of Woe After a couple of tough months, Neurocrine released its second-quarter results. This may be a great stock to own -- if you have the stomach to tolerate the risk.
The Motley Fool December 17, 2004 Brian Gorman	Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls.
The Motley Fool February 6, 2008 Brian Lawler	Neurocrine on the Upswing? Neurocrine Bioscience releases year-end numbers, and updates investors on the status of its top drugs.
The Motley Fool May 8, 2007 Brian Lawler	Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year.
The Motley Fool July 30, 2007 Brian Orelli	Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future.
BusinessWeek May 31, 2004 Gene G. Marcial	Seeking Sepracor? Sepracor is takeover bait because it is just what Big Pharma wants: diversified drugs and the newly approved sleep-disorder medication with blockbuster potential, Estorra.
The Motley Fool October 26, 2004 Charly Travers	Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land?
The Motley Fool July 28, 2010 Jordan DiPietro	3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage
The Motley Fool May 2, 2008 Brian Orelli	Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor.
The Motley Fool March 9, 2004 David Nierengarten	Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%.
The Motley Fool June 27, 2008 Brian Lawler	Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.
The Motley Fool August 25, 2010 Brian Orelli	Shares Soar! That'll Help Investors Sleep Better Tonight. Somaxon finds a marketing partner for its insomnia drug.
The Motley Fool August 13, 2004 Charly Travers	Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition.
The Motley Fool June 23, 2006 Stephen D. Simpson	Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note.
The Motley Fool June 18, 2010 Denise Gellene	San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days The San Diego biotech agreed to grant German drug maker Boehringer Ingelheim and signed a pact with Abbott Labs.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool November 6, 2006 Brian Lawler	Neurocrine's Big Headache Another clinical trial means a steep drop in share price, but the biopharmaceutical's not dead yet. Investors, take note.
BusinessWeek April 23, 2007 Alex Halperin	Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review.
The Motley Fool September 17, 2009 Brian Orelli	Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it.
The Motley Fool October 18, 2004 Charly Travers	Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers?
The Motley Fool August 30, 2004 Charly Travers	It's a Hard-Knock Market You can never eliminate the risk in investing, but you can manage risk by understanding where you're putting your money.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
BusinessWeek January 26, 2004 Arelene Weintraub	"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market.
The Motley Fool September 26, 2007 Billy Fisher	More Than 40 Winks From Arena The company announced positive preliminary results from its phase 2 clinical trial for APD125, which aims to treat people suffering from chronic insomnia. Investors, take note.
The Motley Fool May 16, 2006 Stephen D. Simpson	The FDA Tries to Put Neurocrine to Sleep A surprisingly worded rejection sends two stocks skidding. But setbacks aren't always terminal. While it won't be easy, Neurocrine Biosciences and DOV Pharmaceuticals investors may just want to hang on.
Managed Care November 2006 Martin Sipkoff	Successful Treatment of Insomnia Starts With Formulary Design Many insurers may not consider insomnia a serious health problem, but it costs employers a bundle in lowered productivity.